Study on Mechanism of Intervention of Compound Shenlu Granules in S100A8/A9 for Improving Ineffective Hematopoiesis in Patients with Lower-risk Myelodysplastic Syndrome Click Copy

Study on Mechanism of Intervention of Compound Shenlu Granules in S100A8/A9 for Improving Ineffective Hematopoiesis in Patients with Lower-risk Myelodysplastic Syndrome

References:

[1] 林果为,欧阳仁荣,陈珊珊,等.现代临床血液病学[M].上海:复旦大学出版社,2013:907-908.

[2] CHEN X, EKSIOGLU E A, ZHOU J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells[J]. J Clin Invest,2013, 123(11):4595-4611.

[3] HERMANI A, DE SERVI B, MEDUNJANIN S, et al. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells[J]. Exp Cell Res,2006,312(2):184-197.

[4] 赵琳,邱仲川,江秀花,等.复方补肾冲剂治疗肾阳虚型骨髓增生异常综合征的研究[J].上海医学,2006,29(3):147-149.

[5] 张旭峰,赵琳,徐培.从p38MAPK通路探讨复方参鹿颗粒对较低危MDS骨髓患者CD34+细胞凋亡的影响[J].中国实验方剂学杂志,2017, 23(16):152-157.

[6] 中华医学会血液学分会.骨髓增生异常综合征诊断与治疗专家共识[J].中华血液学杂志,2012,33(4):347-352.

[7] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:178-179.

[8] 张之南.血液病诊断及疗效标准[M].北京:科学出版社,1998:259.

[9] ISHIBASHI M, TAMURA H, OGATA K. Disease progression mechanism in myelodysplastic syndromes:insight into the role of the microenvironment[J]. Leuk Res,2011,35(11):1449-1452.

[10] KORNDÖRFER I P, BRUECKNER F, SKERRA A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins[J]. J Mol Biol,2007,370(5):887-898.

[11] CLUZEAU T, MCGRAW K L, IRVINE B, et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes[J]. Haematologica, 2017,102(12):2015-2020.

[12] LEONI C, MONTAGNER S, RINALDI A, et al. Dnmt3a restrains mast cell inflammatory responses[J]. Proc Natl Acad Sci USA,2017, 114(8):E1490-E1499.

[13] LEE S C, DVINGE H, KIM E, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins[J]. Nat Med,2016,22(6):672-678.

[14] NAVAS T A, MOHINDRU M, ESTES M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors[J]. Blood,2006,108(13):4170-4177.

[15] VARNEY M E, MELGAR K, NIEDERKORN M, et al. Deconstructing innate immune signaling in myelodysplastic syndromes[J]. Exp Hematol, 2015,43(8):587-598.

Memo

基金项目:国家自然科学基金青年基金(81403233)